Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001636587-25-000035·ACORN BIOVENTURES, L.P.
Schedule 13G ownership disclosure
Candel Therapeutics Inc
Common stock, par value $0.0001 per share · CUSIP: 137404109
Event date: 2025-06-25
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ACORN BIOVENTURES, L.P.
Shares: 1,083,818.00 · Class: 2.2%
- ACORN BIOVENTURES 2, L.P.
Shares: 1,496,699.00 · Class: 3.0%
- ACORN CAPITAL ADVISORS GP, LLC
Shares: 1,083,818.00 · Class: 2.2%
- Acorn Capital Advisors GP2, LLC
Shares: 1,496,699.00 · Class: 3.0%
- Anders Hove
Shares: 2,580,517.00 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001636587-25-000035
- Form type
- SCHEDULE 13G
- Filer
- ACORN BIOVENTURES, L.P.
- CIK
- CIK 1766853
- Filed
- Jun 30, 2025
- Reporting period
- Jun 25, 2025
- Description
- Schedule 13G beneficial ownership